Cargando…

Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis

IMPORTANCE: Brolucizumab (Beovu(®)) is an anti-vascular endothelial growth factor (anti-VEGF) agent approved for the treatment of neovascular age-related macular degeneration (nvAMD). Brolucizumab was marketed for its noninferiority to aflibercept and its potential for greater durability. However, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saba, Nicholas J, Walter, Scott D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518423/ https://www.ncbi.nlm.nih.gov/pubmed/37753246 http://dx.doi.org/10.2147/OPTH.S425709

Ejemplares similares

The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study
por: Terauchi, Yasuo, et al.
Publicado: (2022)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
por: Chuan, Junlan, et al.
Publicado: (2022)

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Montesel, Andrea, et al.
Publicado: (2021)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance Study
por: Lee, Hye Jin, et al.
Publicado: (2015)

Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab
por: Igwe, Franklin, et al.
Publicado: (2022)

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022)

Brolucizumab for macular degeneration
Publicado: (2020)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
por: Tanihara, Hidenobu, et al.
Publicado: (2019)

Post-marketing safety surveillance of the rotavirus vaccine in India
por: Kang, Gagandeep, et al.
Publicado: (2023)

Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study
por: Tanihara, Hidenobu, et al.
Publicado: (2020)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Erratum: Side Effects of Brolucizumab
Publicado: (2022)

Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
por: Li, Chunxiao, et al.
Publicado: (2018)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China
por: Meng, Fan-Ya, et al.
Publicado: (2017)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines
por: Albalawi, Omar M., et al.
Publicado: (2022)

An Overview of COVID-19 Vaccine Safety and Post-marketing Surveillance Systems
por: Younus, Manal Mohammed, et al.
Publicado: (2021)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea
por: Choe, Sunho, et al.
Publicado: (2023)

Is This a 737 Max Moment for Brolucizumab?
por: Rosenfeld, Philip J., et al.
Publicado: (2020)

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
por: Coney, Joseph M., et al.
Publicado: (2023)

Three-Month Results of Brolucizumab Intravitreal Therapy in Patients with Wet Age-Related Macular Degeneration
por: Michalska-Małecka, Katarzyna, et al.
Publicado: (2021)

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
por: Komatsu, Yoshito, et al.
Publicado: (2015)

Safety and Efficacy of Melatonin in Chronic Tension-Type Headache: A Post-Marketing Real-World Surveillance Program
por: Danilov, Andrei B., et al.
Publicado: (2020)

Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
por: Ahn, Seo-Yeon, et al.
Publicado: (2022)

Safety and efficacy of Rapamune® (Sirolimus) in kidney transplant recipients: results of a prospective post-marketing surveillance study in Korea
por: Jeon, Hee Jung, et al.
Publicado: (2018)

Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results
por: Hanafusa, Norio, et al.
Publicado: (2017)

Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients
por: Chung, Man Pyo, et al.
Publicado: (2020)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b103jvnei8feukakiebb12fu9b